FDA Okays Weekly Option in Achondroplasia - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

  • By

  • Kathryn Wighton

  • March 2, 2026

  • 2 min

Share

  • 1

    The FDA has granted accelerated approval for navepegritide (YUVIWEL) to enhance growth in pediatric patients with achondroplasia.

  • 2

    Approval was based on improvements in annualized growth velocity from three randomized clinical trials and open-label extension data.

  • 3

    Navepegritide acts as a prodrug of C-type natriuretic peptide, counteracting overactive fibroblast growth factor receptor 3 signaling.

  • 4

    Serious adverse reactions may include hypotension, with common side effects being injection site reactions.

  • 5

    Commercial availability of navepegritide in the US is expected in early Q2 2026.

Original Source(s)

FDA Okays Weekly Option in Achondroplasia

  • by Kathryn Wighton

  • March 2, 2026

Related Content

Risk of Injury Among Children and Youths Whose Mothers Experienced Violent Injury: A Systematic Review and

Contact Lenses as Optical Interventions for Myopia Management

The latest in our myopia series from The European Myopia Network

Enterovirus diversity may limit treatment advances

Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.